To Evaluate the Expression of p53 and Ki67 in Breast Cancer and Their Clinicopathological Correlation with ER PR and HER2/neu

Abstract

Background: Breast cancer is the most common cancer among women in India and with an increasing trend. The combined estrogen receptor (ER), progesterone receptor (PR), and HER2/neu biomarker expression is a predictor of breast cancer status for therapeutic guidance. Studies have demonstrated that these biomarkers are unstable throughout their tumor progression. Varying concordance and discordance in the biomarker expression between ER, PR Her2neu and its correlation with p53 and ki67 status are reported. Aim: This study was conducted for studying and comparing the expression of immunohistochemistry (IHC) markers, i.e., ER, PR, HER2/neu, p53, and Ki67 for clinicopathological features and interrelation purpose. Methods: Fifty one cases of female breast carcinoma between years December 2019 and April 2021 were included in the study. IHC was applied on the sections from tru-cut/excisional biopsies and subsequent mastectomy specimens. Analyses of the expression of IHC markers were attempted. Results: Substantial agreement was observed for biomarker ER, PR, HER2/neu, p53, and Ki67 expression with respect to age of the patient, size of the lump, histologic grade and diagnosis. Conclusion: This study demonstrated a significant association between tumor size with advanced histological grade, high cell proliferation (Ki-67 expression) and p53. Thus, there is a need to perform ER, PR, HER2/neu, p53, and Ki67 IHC studies routinely to help design therapies that are tailored to target the specific tumor clones and render maximum benefit to patients.